APLM Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Apollomics, Inc.'s net margin of --. Apollomics, Inc.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.

Apollomics, Inc. has a consensus price target of --, signalling upside risk potential of 1129.26%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that Apollomics, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Apollomics, Inc. is more attractive than CEL-SCI Corp..

Apollomics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Apollomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apollomics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Apollomics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Apollomics, Inc.'s net income of -- is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Apollomics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apollomics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Apollomics, Inc.'s net margin of -953.4%. Apollomics, Inc.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.

Apollomics, Inc. has a consensus price target of --, signalling upside risk potential of 1129.26%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Apollomics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Apollomics, Inc..

Apollomics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Apollomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apollomics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Apollomics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Apollomics, Inc.'s net income of -- is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Apollomics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apollomics, Inc. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MIRA Pharmaceuticals, Inc. has a net margin of -- compared to Apollomics, Inc.'s net margin of --. Apollomics, Inc.'s return on equity of -- beat MIRA Pharmaceuticals, Inc.'s return on equity of -935.53%.

Apollomics, Inc. has a consensus price target of --, signalling upside risk potential of 1129.26%. On the other hand MIRA Pharmaceuticals, Inc. has an analysts' consensus of $10.38 which suggests that it could grow by 610.62%. Given that Apollomics, Inc. has higher upside potential than MIRA Pharmaceuticals, Inc., analysts believe Apollomics, Inc. is more attractive than MIRA Pharmaceuticals, Inc..

Apollomics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MIRA Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apollomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MIRA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apollomics, Inc. pays -- of its earnings as a dividend. MIRA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Apollomics, Inc. quarterly revenues are --, which are smaller than MIRA Pharmaceuticals, Inc. quarterly revenues of --. Apollomics, Inc.'s net income of -- is lower than MIRA Pharmaceuticals, Inc.'s net income of -$22.7M. Notably, Apollomics, Inc.'s price-to-earnings ratio is -- while MIRA Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apollomics, Inc. is -- versus -- for MIRA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Praxis Precision Medicines, Inc. has a net margin of -- compared to Apollomics, Inc.'s net margin of -786.27%. Apollomics, Inc.'s return on equity of -- beat Praxis Precision Medicines, Inc.'s return on equity of -67.75%.

Apollomics, Inc. has a consensus price target of --, signalling upside risk potential of 1129.26%. On the other hand Praxis Precision Medicines, Inc. has an analysts' consensus of $331.60 which suggests that it could grow by 33.72%. Given that Apollomics, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe Apollomics, Inc. is more attractive than Praxis Precision Medicines, Inc..

Apollomics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Praxis Precision Medicines, Inc. has a beta of 2.946, suggesting its more volatile than the S&P 500 by 194.607%.

Apollomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Praxis Precision Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apollomics, Inc. pays -- of its earnings as a dividend. Praxis Precision Medicines, Inc. pays out -- of its earnings as a dividend.

Apollomics, Inc. quarterly revenues are --, which are smaller than Praxis Precision Medicines, Inc. quarterly revenues of --. Apollomics, Inc.'s net income of -- is lower than Praxis Precision Medicines, Inc.'s net income of -$73.9M. Notably, Apollomics, Inc.'s price-to-earnings ratio is -- while Praxis Precision Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apollomics, Inc. is -- versus 701.87x for Praxis Precision Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.